<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; objectives</title>
	<atom:link href="http://www.tapanray.in/tag/objectives/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>Drug Innovation and Pharma M&amp;As: A Recent Perspective</title>
		<link>http://www.tapanray.in/drug-innovation-and-pharma-mas-a-recent-perspective/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=drug-innovation-and-pharma-mas-a-recent-perspective</link>
		<comments>http://www.tapanray.in/drug-innovation-and-pharma-mas-a-recent-perspective/#comments</comments>
		<pubDate>Mon, 04 Jun 2018 00:00:46 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[acquisition]]></category>
		<category><![CDATA[blockbuster]]></category>
		<category><![CDATA[CEO]]></category>
		<category><![CDATA[critical]]></category>
		<category><![CDATA[deal]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[hefty]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[M&A]]></category>
		<category><![CDATA[merger]]></category>
		<category><![CDATA[objectives]]></category>
		<category><![CDATA[price]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=8949</guid>
		<description><![CDATA[The 21st CEO Survey 2018 of PwC highlights a curious contradiction. This is based on what the Global Pharma Chief Executive Officers (CEOs) had articulated regarding their business outlook for 2018 and beyond. The report says: Despite highly publicized hand &#8230; <a href="http://www.tapanray.in/drug-innovation-and-pharma-mas-a-recent-perspective/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/drug-innovation-and-pharma-mas-a-recent-perspective/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Pharmaceutical innovation and Public Health Interest: Ways to achieving the dual objectives</title>
		<link>http://www.tapanray.in/pharmaceutical-innovation-and-public-health-interest-ways-to-achieving-the-dual-objectives/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=pharmaceutical-innovation-and-public-health-interest-ways-to-achieving-the-dual-objectives</link>
		<comments>http://www.tapanray.in/pharmaceutical-innovation-and-public-health-interest-ways-to-achieving-the-dual-objectives/#comments</comments>
		<pubDate>Mon, 06 Feb 2012 00:00:50 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[achieving]]></category>
		<category><![CDATA[Affordability]]></category>
		<category><![CDATA[and]]></category>
		<category><![CDATA[dual]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[interest]]></category>
		<category><![CDATA[local]]></category>
		<category><![CDATA[MNC]]></category>
		<category><![CDATA[objectives]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[public]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[the]]></category>
		<category><![CDATA[to]]></category>
		<category><![CDATA[Ways]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=137</guid>
		<description><![CDATA[Healthcare industry in general and the pharmaceutical sector in particular have been experiencing  a plethora of innovations not only to cure and effectively manage ailments to improve the quality of life, but also to help increasing overall disease-free life expectancy &#8230; <a href="http://www.tapanray.in/pharmaceutical-innovation-and-public-health-interest-ways-to-achieving-the-dual-objectives/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/pharmaceutical-innovation-and-public-health-interest-ways-to-achieving-the-dual-objectives/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>How have the ‘Drug Policies’ of India fared against the set objectives?</title>
		<link>http://www.tapanray.in/how-have-the-drug-policies-of-india-fared-against-the-set-objectives/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=how-have-the-drug-policies-of-india-fared-against-the-set-objectives</link>
		<comments>http://www.tapanray.in/how-have-the-drug-policies-of-india-fared-against-the-set-objectives/#comments</comments>
		<pubDate>Thu, 15 Oct 2009 01:30:47 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[Affordability]]></category>
		<category><![CDATA[against]]></category>
		<category><![CDATA[cheap]]></category>
		<category><![CDATA[delivery]]></category>
		<category><![CDATA[DoP]]></category>
		<category><![CDATA[DPCO]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[fared]]></category>
		<category><![CDATA[generics]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[infrastructure]]></category>
		<category><![CDATA[MoH]]></category>
		<category><![CDATA[objectives]]></category>
		<category><![CDATA[of]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[Policies]]></category>
		<category><![CDATA[price]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[set]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[the]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=754</guid>
		<description><![CDATA[Indian Pharmaceutical Industry has by now established itself as one of the most important knowledge based industry of the nation with significant sets of differential advantages. It has earned global recognition as a low cost producer and global supplier of &#8230; <a href="http://www.tapanray.in/how-have-the-drug-policies-of-india-fared-against-the-set-objectives/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/how-have-the-drug-policies-of-india-fared-against-the-set-objectives/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
